Lab Informatics Integration Remains Key Challenge

- Poor data integration can cause pharmaceutical companies to lose 15-20% of their potential manufacturing efficiency, which for a mid-sized company with $2 billion in annual revenue, can amount to $300-400 million in lost productivity each year. - In the cell and gene therapy (CGT) sector, the lack of data standardization is a significant obstacle, as process data, quality metrics, and clinical outcomes are often stored in separate databases, which prevents a unified view of performance. Initiatives are emerging to standardize the entire "vein-to-vein" process to reduce inefficiencies and improve patient access. - Digital twins are being adopted in bioprocessing to create virtual replicas of manufacturing processes, which allows for the simulation of scenarios to optimize equipment performance, reduce operational bottlenecks, and predict maintenance needs. This technology relies on real-time data from bioreactors and analytical instruments to model and control complex biological operations like cell culture and fermentation. - The implementation of Electronic Batch Records (EBRs) is often hindered by the challenge of integrating them with a variety of existing systems, such as MES, LIMS, and ERP systems, a task that requires a deep understanding of the data flows between these different platforms. One study found that EBRs can lead to a 75% decrease in human errors compared to paper-based systems. - A 2026 Deloitte survey indicated that only 22% of life sciences leaders have successfully scaled AI, with data quality and integration being cited as major technical barriers. Inconsistent, siloed, and poorly contextualized historical data is often unsuitable for training reliable AI/ML models for tasks like titer prediction. - To differentiate themselves, Contract Development and Manufacturing Organizations (CDMOs) are increasingly investing in digital technologies like automation and AI-driven analytics to offer real-time visibility into production data, which helps to speed up decision-making. The global pharmaceutical CDMO market was valued at USD 185 billion in 2024 and is projected to reach USD 368.7 billion by 2034. - The challenge of integrating different informatics systems often leads to "hybrid" records, where electronic data from computerized systems are used to create paper records that are then signed by hand, increasing the risk of non-compliance and batch review times. - A survey by the American Management Association revealed that 83% of executives believe their companies have data silos, and 97% of those executives think these silos have a negative impact on the business. In a separate study, 53% of pharmaceutical companies with over $1 billion in annual revenue reported that data silos hinder or prevent cross-functional collaboration.